Sugi Predict

Sugi Predict / Compounds / SCHEMBL351889

SCHEMBL351889

SCHEMBL351889

O=C(Cl)CCCOc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA3 P22001 1/20 0.58
▸ HDAC1 Q13547 2/20 0.54
▸ HDAC2 Q92769 2/20 0.54
▸ HPGD P15428 3/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ PKM P14618 1/20 0.53
▸ TAAR1 Q96RJ0 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ L3MBTL1 Q9Y468 3/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ MAPK1 P28482 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6641305 0.94 HDAC1 (0.62) KCNA3HDAC1HDAC2PKMALDH1A1
SCHEMBL3277574 0.92 HDAC1 (0.65) KCNA3HDAC1HDAC2
SCHEMBL1308374 0.90 CYP1A2 (0.58) KCNA3HDAC1HDAC2NPC1RAB9A
SCHEMBL10361230 0.83 KCNA3 (0.62) KCNA3HDAC1HDAC2HPGDNPC1
SCHEMBL295889 0.83 PPARA (0.66) KCNA3HDAC1HDAC2HPGDNPC1
SCHEMBL4532106 0.83 FFAR1 (0.68) KCNA3TAAR1L3MBTL1TDP1LMNA
SCHEMBL20565530 0.82 KMT2A (0.58) HPGDRAB9AALDH1A1L3MBTL1CYP1A2
SCHEMBL1326062 0.82 PARP10 (0.61) KCNA3HDAC1HDAC2HPGDNPC1
SCHEMBL10403408 0.82 KCNA3 (0.60) KCNA3HDAC1HDAC2HPGDNPC1
Hydrochloric Acid SCHEMBL7685353 0.82 PPARA (0.64) KCNA3HDAC1HDAC2HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116199616-A Modified oxime ester compound, preparation method thereof and photo-curing composition 常州强力电子新材料股份有限公司 2023-06-02 — — CN claimed
CN-116199617-A Oxime ester compound, preparation method thereof and photo-curing composition 常州强力电子新材料股份有限公司 2023-06-02 — — CN claimed
EP-0440329-A1 S-substituted carbonyl substituted betathioacrylamide biocides and fungicides ROHM AND HAAS COMPANY (US) 1991-08-07 — — EP claimed
CN-116199617-A Oxime ester compound, preparation method thereof and photo-curing composition 常州强力电子新材料股份有限公司 2023-06-02 — — CN disclosed
CN-116199616-A Modified oxime ester compound, preparation method thereof and photo-curing composition 常州强力电子新材料股份有限公司 2023-06-02 — — CN disclosed
CN-110921853-B Anticorrosive environment-friendly scale remover capable of rapidly removing scale and preparation method and application thereof 北京杰信越发制冷设备安装工程有限公司 2022-05-27 — — CN disclosed
CN-112574239-B 3-thiazolenyl boron fluoride complex dipyrromethene compound and preparation method and application thereof 中国科学院上海药物研究所 2022-03-25 — — CN disclosed
CN-112574239-A 3-thiazolenyl boron fluoride complex dipyrromethene compound and preparation method and application thereof 中国科学院上海药物研究所 2021-03-30 — — CN disclosed
CN-110921853-A Anticorrosive environment-friendly scale remover capable of rapidly removing scale and preparation method and application thereof 北京杰信越发制冷设备安装工程有限公司 2020-03-27 — — CN disclosed
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 — — EP disclosed
EP-2344493-B1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2016-01-06 — — EP disclosed
WO-2003045379-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS KINETEK PHARMACEUTICALS, INC. (CA) 2003-06-05 — — WO disclosed
US-20030060629-A1 Pyrazine derivatives as modulators of tyrosine kinases ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-03-27 — — US disclosed
US-6455538-B1 SODIUM CHANNEL MODULATORS; BRAIN AND NERVOUS SYSTEM DISORDERS BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-09-24 — — US disclosed
WO-2002024681-A2 PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-03-28 — — WO disclosed
US-6159996-A Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-12-12 — — US disclosed
US-5300672-A For water systems, plant diseases ROHM AND HAAS COMPANY (US) 1994-04-05 — — US disclosed
US-5194442-A 2,3,4,5-tetrahydro-1-benzoxepins, the use thereof and pharmaceutical products based on these compounds HOECHST AKTIENGESELLSCHAFT (DE) 1993-03-16 — — US disclosed
US-5166390-A Bactericides ROHM AND HAAS COMPANY (US) 1992-11-24 — — US disclosed
EP-0440329-A1 S-substituted carbonyl substituted betathioacrylamide biocides and fungicides ROHM AND HAAS COMPANY (US) 1991-08-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060629-A1 Pyrazine derivatives as modulators of tyrosine kinases FLT1, FLT4, KDR KCNA3 3269/4885HDAC1 1599/4885HDAC2 1573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.